Table 2. Methodological and clinico-pathological data for eligible prognostic studies evaluating VEGF, bcl-2, bax and p16.
| Reference | n | HR (95% CI) | Significant | 1° Ab (+dilution) | IHC +ve | IHC cutoff (%) | Male | Age | N1 | T3/T4 | Well | Mod. | Poor | Adjuvant therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VEGF | ||||||||||||||
| Itakura et al (1997) | 75 | 1.12 (0.69–1.82) | No | NC (30 μg ml–1) | 48 (64) | >10 | 46 (61) | 62 | 47 (63) | 43 (57) | 13 (17) | 44 (59) | 18 (24) | NS |
| Fujimoto et al (1998) | 50 | 0.78 (0.44–1.40) | No | Santa Cruz A20 (1 : 200) | 28 (40) | NS | 28 (56) | 62 | 29 (58) | 34 (68) | 9 (18) | 31 (62) | 10 (20) | NS |
| Seo et al (2000) | 142 | 1.46 (1.02–2.09) | Yes | Santa Cruz (NS) | 94 (66) | >30 | 79 (56) | 64 | 95 (67) | NS | NS | NS | NS | NS |
| Ikeda et al (2001) | 48 | 2.74 (1.44–5.20) | Yes | Santa Cruz (1 : 200) | 31 (65) | >10 | 37 (77) | 64 | 24 (50) | 40 (83) | 15 (31) | 28 (58) | 5 (11) | 48 (100) |
| Knoll et al (2001) | 19 | 2.37 (0.88–6.40) | No | R&D Ab293NA (1 : 200) | 13 (68) | >5 | 11 (58) | 58 | 18 (95) | 1 (5) | 1 (5) | 12 (63) | 6 (32) | 0 (0) |
| Niedergethmann et al (2002) | 70 | 2.48 (1.22–5.05) | Yes | Santa Cruz (1 : 200) | 28 (40) | >10 | 42 (60) | 63 | 41 (59) | NS | 25 (36) | 45 (64) | 22 (31) | |
| Kuwahara et al (2003) | 55 | 2.08 (1.12–3.88) | Yes | Santa Cruz sc152 (1 : 200) | 39 (71) | >50 | 34 (62) | 64 | 30 (55) | 40 (73) | 13 (24) | 33 (60) | 9 (16) | NS |
| Lim et al (2004) | 72 | 0.82 (0.49–1.37) | No | Santa Cruz (1 : 2000) | 23 (32) | >10 | 43 (60) | 60 | 38 (53) | 59 (82) | 14 (19) | 44 (61) | 14 (19) | 26 (36) |
| Khorana et al (2005) | 124 | 1.30 (0.87–1.95) | No | Zymed (1 : 50) | 70 (56) | >5 | 69 (56) | 67 | 56 (45) | 69 (58) | 23 (19) | 52 (43) | 45 (38) | 88 (79) |
| Tang et al (2006) | 50 | 1.46 (0.84–2.54) | No | NS (2 μg ml–1) | 25 (50) | >10 | 25 (50) | 63 | 39 (78) | 25 (50) | 15 (30) | 31 (62) | 4 (8) | NS |
| Ai et al (2008) | 62 | 2.34 (1.41–3.89) | Yes | Neomarkers (NS) | 37 (60) | >10 | 36 (58) | 65 | 49 (79) | 32 (52) | 17 (27) | 15 (24) | 30 (48) | 0 (0) |
| bcl-2 | ||||||||||||||
| Bold et al (1999) | 70 | 0.64 (0.35–1.18) | No | DAKO (NS) | 23 (33) | >25% | 36 (51) | 64 | 32 (46) | NS | 15 (22) | 37 (55) | 15 (22) | 19 (27) |
| Nio et al (2001b) | 66 | 0.45 (0.25–0.82) | Yes | DAKO M0887 (1 : 100) | 16 (24) | >5% | 31 (47) | 66 | 54 (82) | NS | 33 (50) | 29 (44) | 4 (6) | 36 (55) |
| Magistrelli et al (2006) | 67 | 0.56 (0.33–0.96) | Yes | DAKO c124 (1 : 40) | 45 (67) | >5% | 45 (67) | 63 | 34 (51) | 40 (62) | 14 (21) | 28 (42) | 15 (22) | 30 (45) |
| Sarela et al (2002) | 52 | 0.50 (0.08–3.33) | No | DAKO (1 : 40) | 6 (12) | >10% | 27 (52) | 64 | 40 (78) | 49 (94) | 11 (22) | 24 (47) | 16 (31) | NS |
| Dong et al (2005b) | 59 | 0.43 (0.25–0.74) | Yes | DAKO M124(1 : 100) | 21 (36) | >5% | 19 (32) | 55 | 54 (82) | NS | 19 (32) | 21 (36) | 19 (32) | NS |
| bax | ||||||||||||||
| Friess et al (1998) | 60 | 0.47 (0.23–0.97) | Yes | Santa Cruz (NS) | 50 (83) | NS | 32 (53) | 63 | 38 (63) | NS | NS | NS | NS | NS |
| Evans et al (2001) | 23 | 0.80 (0.28–2.29) | No | Santa Cruz (1 : 1600) | 6 (26) | >5% | 15 (65) | 59 | 38 (63) | NS | 5 (22) | 13 (54) | 5 (22) | 0 (0) |
| Nio et al (2001b) | 65 | 0.49 (0.28–0.85) | Yes | DAKO A3533 (1 : 100) | 42 (65) | >10% | 31 (47) | 66 | 54 (82) | NS | 33 (50) | 29 (44) | 4 (6) | 36 (55) |
| Magistrelli et al (2006) | 67 | 0.56 (0.33–0.95) | Yes | Zymed c2D2 (1 : 80) | 36 (54) | >10% | 45 (67) | 63 | 34 (51) | 40 (62) | 14 (21) | 28 (42) | 15 (22) | 30 (45) |
| Dong et al (2005b) | 59 | 0.93 (0.57–1.52) | No | DAKO A3533 (1 : 100) | 29 (49) | >10% | 19 (32) | 55 | 54 (82) | NS | 19 (32) | 21 (36) | 19 (32) | NS |
| p16 | ||||||||||||||
| Naka et al (1998) | 32 | 0.45 (0.21–0.96) | Yes | Santa Cruz C20 (1 : 500) | 19 (59) | NS | 20 (63) | 65 | 23 (72) | 13 (41) | NS | NS | NS | NS |
| Kawesha et al (2000) | 157 | 0.82 (0.50–1.33) | No | Santa Cruz (1 : 100) | 21 (13) | >5% | 100 (64) | 60 | 71 (46) | NS | 21 (13) | 77 (49) | 59 (38) | 13 (8) |
| Gerdes et al (2002) | 40 | 0.51 (0.25–1.04) | No | Pharmingen G175–405 (1 : 50) | 13 (33) | >5% | 22 (55) | NS | 16 (40) | NS | NS | NS | NS | 0 (0) |
Abbreviations: CI=confidence interval; HR=hazard ratio; IHC=immunohistochemical; NC=non-commercial; NS=not specified; VEGF=vascular endothelial growth factor.
% in parentheses unless otherwise stated. IHC and/or clinico-pathological data were incompletely reported in some studies. Well/Mod/Poor refers to tumour differentiation.